Diagnostic Value of Serum and Urine Endocan Levels in Nonmuscle Invasive Bladder Cancer: A Prospective Comparative Study
Open Access
- 30 April 2024
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2024, 1-7
Abstract
Objective. This prospective study aimed to explore the potential diagnostic value of endocan levels in bladder cancer by investigating a possible association of serum and urine endocan levels with the stage and grade of bladder tumors in patients with nonmuscle-invasive bladder cancer (NMIBC) in terms of risk stratification. Materials and Methods. Participants included 66 male patients with NMIBC. Patients with full pathology results, NMIBC stage T1, and healthy controls were categorized as groups 1, 2, and 3, respectively. Patients were further classified into high- and low-grade groups following their pathology results. Risk classification according to the European Association of Urology (EAU) was assigned to patients with NMIBC, and associations of risk groups with serum and urine endocan levels were analyzed. An enzyme-linked immunosorbent assay was used to identify serum and urine endocan concentrations. Results. Serum endocan levels according to pathological staging were significantly higher in groups 1 and 2 than in group 3. The urine endocan level was statistically significantly higher in group 2 than in group 3 . The predictive power of the urine endocan level was evaluated for its ability to predict T1 disease, revealing an area under the curve of 0.735 and a threshold of 903. The EAU classification was evaluated according to risk groups, and the urine endpoint was statistically significantly higher in the univariate analysis for the high and very high-risk groups . Conclusion. Our results indicate that endocan levels hold significant promise in prognostic feature evaluation in NMIBC, particularly in the context of screening patients with hematuria.Keywords
Funding Information
- Atatürk Üniversitesi (7178)
This publication has 20 references indexed in Scilit:
- Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk FactorsEuropean Urology, 2023
- The global burden of urinary bladder cancer: an updateWorld Journal of Urology, 2019
- What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic ReviewEuropean Urology Oncology, 2019
- Bladder cancerNature, 2017
- Endocan measurement for the postmortem diagnosis of sepsisLegal Medicine, 2014
- Contemporary management of low-risk bladder cancerNature Reviews Urology, 2011
- Staging and reporting of urothelial carcinoma of the urinary bladderLaboratory Investigation, 2009
- Endocan Expression Correlated with Poor Survival in Human Hepatocellular CarcinomaDigestive Diseases and Sciences, 2008
- Gene polymorphisms in bladder cancerUrologic Oncology: Seminars and Original Investigations, 2008
- Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2006